source
- Apnimed secures $192 million IPO to fund sleep-apnea drug program targeting 2027 launchApnimed, a biotech focused on sleep apnea, announced it raised $192 million through an initial public offering. The capital will be used to advance its lead drug candidate, with plans to begin a l…
- FDA announces reorganization and CTAGTAC votes on Duchenne muscular dystrophy and melanoma therapiesThe FDA disclosed a major internal reorganization aimed at streamlining its operations and improving efficiency across its divisions. The agency’s Cellular, Tissue, and Gene Therapies Advisory Com…